Key points from article :
Terray Therapeutics, a biotech company founded by brothers Jacob and Eli Berlin, recently announced a partnership with Odyssey Therapeutics and raised $120 million in a Series B funding round. The company, launched in 2022, uses computational analysis and artificial intelligence to speed up drug discovery. The Series B funding round is double the amount of their Series A round, indicating growing confidence in their platform.
The company’s drug discovery platform, tNova, aims to reduce the time it takes for a drug to reach approval. Typically, new drugs can take up to 10 years to get FDA approval, with the majority failing during the development process, costing around $1 billion per drug. Terray’s platform seeks to streamline this by analyzing chemical compounds in various combinations to identify the most promising options.
The goal of the platform is to reduce drug development time and lower costs by improving the selection process. The company uses advanced technologies to predict which compounds are most likely to succeed in animal testing, clinical trials, and FDA reviews. This approach could significantly change how drugs are developed.
Jacob Berlin, the company’s CEO, explained that their core technology doesn't prescribe a fixed path but rather enables flexible, effective drug development. The company has focused its efforts on small molecule drug development, particularly for autoimmune and immunology disorders, which are areas with significant unmet needs.
The announcement of the partnership with Odyssey Therapeutics follows the success of their funding round and is part of their broader strategy to expand their reach and capabilities in drug development. This collaboration will likely help Terray further develop and refine its platform, making it more attractive to pharmaceutical companies.
Terray Therapeutics is based in Monrovia, and their research is supported by substantial venture capital, signaling strong investor confidence in their innovative approach to drug discovery. The company’s efforts could potentially transform the landscape of drug development, making it more efficient and affordable.
